An Update on FDAs Critical Path Initiative Statistical Contributions Robert T. ONeill Ph.D. Director, Office of Biostatistics Center for Drug Evaluation.
William Shrank M.D. MSHS Division of Pharmacoepidemiology & Pharmacoeconomics Brigham & Womens Hospital, Harvard Medical School.
Joseph A. DiMasi, Ph.D. Director of Economic Analysis Tufts Center for the Study of Drug Development Tufts University SLA Pharmaceutical & Health Technology.
The Pharmaceutical Promotional Literature A Users Guide.
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Army Human Terrain Team Ft. Leavenworth, Kansas October 14, 2008 Dr. Robert E. Looney [email protected] The Afghan Economy II: Implementing Reconstruction.
Bernhard Huitfeldt 24 Oct 20121 FMS and the development of biostatistics during 25 years (mostly from a pharma industry perspective) FMS jubilee conference.
Los Precios de los Medicamentos en USA Enrique Seoane Vazquez, Ph.D. Assistant Professor Pharmaceutical Economics and Policy College of Farmacia and College.
The value of social media to public affairs
Research Management Tools
Grønsværet
Cpc system presentation final
